Tumor-Associated CD204-Positive Macrophage Is a Prognostic Marker in Clinical Stage I Lung Adenocarcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor-Associated CD204-Positive Macrophage Is a Prognostic Marker in Clinical Stage I Lung Adenocarcinoma
Authors
Keywords
-
Journal
Biomed Research International
Volume 2018, Issue -, Pages 1-7
Publisher
Hindawi Limited
Online
2018-04-17
DOI
10.1155/2018/8459193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD163+CD204+ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma
- (2017) Keigo Kubota et al. Scientific Reports
- Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung
- (2016) Masahito Naito et al. LUNG CANCER
- Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
- (2015) Thomas K. Kilvaer et al. PLoS One
- Prognostic Significance of CD204-Positive Macrophages in Upper Urinary Tract Cancer
- (2014) Takashi Ichimura et al. ANNALS OF SURGICAL ONCOLOGY
- American Cancer Society lung cancer screening guidelines
- (2013) Richard Wender et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma
- (2013) Manabu Shigeoka et al. CANCER SCIENCE
- M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway
- (2013) Chao-Ying Liu et al. LABORATORY INVESTIGATION
- Tumor microenvironment and lymphocyte infiltration
- (2012) Gwendoline Rahir et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prognostic Impact of Cancer-Associated Stromal Cells in Patients With Stage I Lung Adenocarcinoma
- (2012) Masami Ito et al. CHEST
- Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment
- (2012) T. Lu et al. CLINICAL CANCER RESEARCH
- Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting Microenvironment
- (2012) Shunki Hirayama et al. Journal of Thoracic Oncology
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Identification and manipulation of tumor associated macrophages in human cancers
- (2011) Moniek Heusinkveld et al. Journal of Translational Medicine
- Refined Prognostic Role of CD68-Positive Tumor Macrophages in the Context of the Cellular Micromilieu of Classical Hodgkin Lymphoma
- (2011) Alexandar Tzankov et al. PATHOBIOLOGY
- Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma
- (2010) Yoichi Ohtaki et al. Journal of Thoracic Oncology
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Regulation of Class A scavenger receptor-mediated cell adhesion and surface localization by PI3K: identification of a regulatory cytoplasmic motif
- (2009) J. Cholewa et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer
- (2009) Hiroshi Kurahara et al. JOURNAL OF SURGICAL RESEARCH
- Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis
- (2009) Daisuke Matsubara et al. MODERN PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now